Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CHAARM

Financiado

Cerrado

Combined Highly Active Anti retroviral Microbicides

This proposal is for a large scale collaborative project in which we propose both to develop novel microbicides directed against new intracellular targets and to investigate novel combinations of highly active anti-retroviral drug... ver más

30/06/2015

KINGS COLLEGE LOND...

17M€

Presupuesto del proyecto: 17M€

Líder del proyecto

KINGS COLLEGE LONDON No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 33 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2015-06-30 No tenemos la información de la convocatoria

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

33 Participantes

KINGS COLLEGE LONDON

0.00€ | Lider

UNIROMA1

N.D. | Participante

UDUS

N.D. | Participante

ITM

N.D. | Participante

Proyectos interesantes

microMAGNETOFLUIDICS

Medical Technol...

Data Science

187K€ Cerrado

Perseus MAP

Medical Technol...

Data Science

4M€ Cerrado

PROMETEO

Medical Technol...

Data Science

Cerrado

HIV ACE

Medical Technol...

Data Science

5M€ Cerrado

EvoSpa

Medical Technol...

Data Science

175K€ Cerrado

PID2021-127318OB-I00

Medical Technol...

Data Science

133K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

KINGS COLLEGE LONDON No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 17M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto This proposal is for a large scale collaborative project in which we propose both to develop novel microbicides directed against new intracellular targets and to investigate novel combinations of highly active anti-retroviral drugs which may be particularly effective as microbicides. Combinations may enhance efficacy but equally importantly will increase the genetic barrier to the development of resistance. The proposal includes development of both slow release and gel formulations, pharmacokinetic and challenge experiments in macaques as well as human studies including a collaborative study with an EDCTP-funded project to use multiplex and proteomic technologies as well as culture-independent DNA-based analysis of mucosal microbiota to investigate biomarkers and establish a baseline signature from which perturbations can be recognised. This is a large consortium comprising 30 partners from 8 EU countries and from Switzerland, Ukraine, South Africa and the United States.Partners include microbicide developers, IPM and Particle Sciences, and producers, Gilead, Tibotec and Virco. Two SMEs will also participate in RTD aspects. The consortium is multidisciplinary with scientists engaged in basic discovery working with new targets and developing novel chemistry to produce compounds with improved safety and efficacy profiles as well as altered patterns of resistance.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores